Vascular Invasion Predicts Recurrence in Stage IA2-IB Lung Adenocarcinoma but not Squamous Cell Carcinoma

被引:3
|
作者
Suaiti, Lubna [1 ]
Sullivan, Travis B. [2 ]
Rieger-Christ, Kimberly M. [2 ]
Servais, Elliot L. [3 ]
Suzuki, Kei [4 ,6 ]
Burks, Eric J. [1 ,2 ,5 ]
机构
[1] Boston Univ, Boston Med Ctr, Dept Pathol & Lab Med, Sch Med, Boston, MA USA
[2] Lahey Hosp & Med Ctr, Dept Translat Res, Ian C Summerhayes Cell & Mol Biol Lab, Burlington, MA USA
[3] Lahey Hosp & Med Ctr, Dept Surg, Burlington, MA USA
[4] Boston Univ, Boston Med Ctr, Dept Surg, Sch Med, Boston, MA USA
[5] Boston Univ Mallory Pathol Associates, Dept Pathol & Labora tory Med, 670 Albany St,Suite 304, Boston, MA 02118 USA
[6] INOVA, Dept Surg, Div Thorac Surg, Falls Church, VA USA
关键词
Lymphovascular; AJCC; NCCN; Pathology; Adjuvant; LYMPHOVASCULAR INVASION; PROGNOSTIC IMPACT; VESSEL INVASION; MICROVASCULAR INVASION; LYMPHATIC INVASION; NUCLEAR-DIAMETER; PRIMARY TUMOR; BLOOD-VESSEL; CANCER; INDICATOR;
D O I
10.1016/j.cllc.2022.12.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
NCCN-guidelines list vascular invasion (VI) as a risk-factor warranting consideration of adjuvant therapy among stage IB NSCLC. Among resected stage IA2-IB LUAD (n =344) and LUSC (n =102), VI predicted worse 5-year RFS for LUAD (64% vs. 90%, P <0.001) but not LUSC (83% vs. 80%, P =0.852). Guidelines should be modified to specify VI as a risk-factor only for stage I adenocarcinoma. Background: Lymphovascular invasion (LVI) is an adverse prognostic feature in resected stage I non-small cell lung cancer (NSCLC); however, it is unclear if the prognostic significance applies to both lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). Materials and Methods: A retrospective review of H&E-stained slides from surgically resected AJCC 8th ed. stage IA2-IB LUAD (n = 344) and LUSC (n = 102) from two institutions was performed. LVI was defined as either lymphatic (LI) or vascular (VI) invasion. Outcomes were assessed by 5-year recurrence-free survival (RFS) estimates using the Kaplan-Meier method. Results: The cohorts of LUAD and LUSC showed no significant differences in 5-year RFS (81% each), stage, age, race, or surgical procedure. The presence of LVI, VI, and LI was predictive of 5-year RFS for LUAD (LVI + 71% vs. LVI -92%, P < 0.001; VI + 64% vs. VI -90%, P < 0.001; LI + 75% vs. LI -84%, P = 0.030) but not LUSC (LVI + 84% vs. LVI -79%, P = 0.740; VI + 83% vs. VI-80%, P = 0.852; LI + 84% vs. LI -81%, P = 0.757). Among LUAD with LVI, VI was a stronger predictor of 5-year RFS than the remaining subset of VI-LI + tumors (64% vs. 87%, P = 004). Subset analysis of LI among LUAD stratified by VI showed no significant prognostic advantage to adding LI for risk stratification (VI-LI + 87% vs. VI-LI -92%, P = 0.347 & VI + LI + 62% vs. VI + LI-66%, P = 0.422). VI was present in 36% of LUAD. Conclusion: Vascular invasion is a strong predictor of recurrence in stage IA2-IB LUAD but not in LUSC. Adjuvant therapy trials should be directed at this subgroup.
引用
收藏
页码:E126 / E133
页数:8
相关论文
共 50 条
  • [31] Neoadjuvant chemotherapy in Stage IB2 squamous cell carcinoma of the cervix
    Serur, E
    Mathews, RP
    Gates, J
    Levine, P
    Maiman, M
    Remy, JC
    GYNECOLOGIC ONCOLOGY, 1997, 65 (02) : 348 - 356
  • [32] Differences Between Squamous Cell Carcinoma and Adenocarcinoma of the Lung: Are Adenocarcinoma and Squamous Cell Carcinoma Prognostically Equal?
    Kawase, Akikazu
    Yoshida, Junji
    Ishii, Genichiro
    Nakao, Masayuki
    Aokage, Keiju
    Hishida, Tomoyuki
    Nishimura, Mitsuyo
    Nagai, Kanji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (03) : 189 - 195
  • [33] Contemporary recurrence and survival outcomes for stage IB squamous cell carcinoma of the vulva: Time to raise the bar
    Stone, R. L.
    Gornet, M.
    Berger, J.
    Sullivan, S. A.
    Gunderson, C. C.
    Acuna, J.
    Zorn, K. K.
    Tanner, E. J., III
    Ojalvo, L.
    Fader, A. Nickles
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 29 - 29
  • [34] Differences in the early stage gene expression profiles of lung adenocarcinoma and lung squamous cell carcinoma
    Venugopal, Nitin
    Yeh, Justin
    Kodeboyina, Sai Karthik
    Lee, Tae Jin
    Sharma, Shruti
    Patel, Nikhil
    Sharma, Ashok
    ONCOLOGY LETTERS, 2019, 18 (06) : 6572 - 6582
  • [35] A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB-IIA cervical cancer
    Xie, Xiuzhen
    Song, Kun
    Cui, Baoxia
    Jiang, Jie
    Yang, Xingsheng
    Kong, Beihua
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) : 522 - 531
  • [36] Impact of lymph node evaluation standard in patients undergoing lung resection for clinical stage IA pulmonary adenocarcinoma and squamous cell carcinoma
    Rocco, Raffaele
    Hendriksen, Brandon S.
    Ortiz, Belisario A.
    Shen, K. Robert
    Cassivi, Stephen D.
    Saddoughi, Sahar
    Reisenauer, Janani S.
    Wigle, Dennis A.
    Tapias, Luis F.
    JOURNAL OF THORACIC DISEASE, 2024, 16 (11)
  • [37] Lymphatic Vessel Invasion is a Significant Prognostic Indicator in Stage IA Lung Adenocarcinoma
    Funai, Kazuhito
    Sugimura, Haruhiko
    Morita, Toyohiko
    Shundo, Yasumasa
    Shimizu, Kei
    Shiiya, Norihiko
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (10) : 2968 - 2972
  • [38] Lymphatic Vessel Invasion is a Significant Prognostic Indicator in Stage IA Lung Adenocarcinoma
    Kazuhito Funai
    Haruhiko Sugimura
    Toyohiko Morita
    Yasumasa Shundo
    Kei Shimizu
    Norihiko Shiiya
    Annals of Surgical Oncology, 2011, 18 : 2968 - 2972
  • [39] Genetic Landscape and Immune Microenvironment Features in Recurrence in Stage IA of Lung Adenocarcinoma
    Yang, L.
    Zhang, J.
    Xu, H.
    Yang, G.
    Xu, F.
    Song, Y.
    Shi, X.
    Wu, L.
    Zhang, H.
    Ying, J.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S520 - S520
  • [40] Prognostic Impact of Preoperative Tumor Marker Levels and Lymphovascular Invasion in Pathological Stage I Adenocarcinoma and Squamous Cell Carcinoma of the Lung
    Kinoshita, Tomonari
    Ohtsuka, Takashi
    Yotsukura, Masaya
    Asakura, Keisuke
    Goto, Taichiro
    Kamiyama, Ikuo
    Otake, Sotaro
    Tajima, Atsushi
    Emoto, Katsura
    Hayashi, Yuichiro
    Kohno, Mitsutomo
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (04) : 619 - 628